Panion & Bf Biotech Inc. (1760.TW)
TWD 67.3
(2.75%)
TWD 67.3
(2.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 156.82 Million TWD | -54.02% |
| 2022 | 341.07 Million TWD | 71.03% |
| 2021 | 199.42 Million TWD | 104.92% |
| 2020 | 97.31 Million TWD | -57.34% |
| 2019 | 228.11 Million TWD | 7.62% |
| 2018 | 211.97 Million TWD | 46.47% |
| 2017 | 144.72 Million TWD | 11.65% |
| 2016 | 129.62 Million TWD | 8.05% |
| 2015 | 119.96 Million TWD | 86.29% |
| 2014 | 64.39 Million TWD | 363.92% |
| 2013 | 13.88 Million TWD | 129.09% |
| 2012 | -47.71 Million TWD | -0.61% |
| 2011 | -47.42 Million TWD | 14.39% |
| 2010 | -55.39 Million TWD | -1512.01% |
| 2009 | 3.92 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 37.45 Million TWD | -33.22% |
| 2024 Q1 | 56.08 Million TWD | -1.89% |
| 2023 Q4 | 57.16 Million TWD | 62.67% |
| 2023 FY | 156.82 Million TWD | -54.02% |
| 2023 Q1 | 53.43 Million TWD | 158.94% |
| 2023 Q2 | 40.1 Million TWD | -24.96% |
| 2023 Q3 | 35.14 Million TWD | -12.37% |
| 2022 Q1 | 68.13 Million TWD | 164.86% |
| 2022 Q3 | 127.91 Million TWD | -45.73% |
| 2022 Q4 | -90.66 Million TWD | -170.88% |
| 2022 FY | 341.07 Million TWD | 71.03% |
| 2022 Q2 | 235.69 Million TWD | 245.93% |
| 2021 Q3 | 66.17 Million TWD | -23.21% |
| 2021 Q4 | 25.72 Million TWD | -61.13% |
| 2021 FY | 199.42 Million TWD | 104.92% |
| 2021 Q1 | -641 Thousand TWD | -101.24% |
| 2021 Q2 | 86.17 Million TWD | 13543.99% |
| 2020 Q4 | 51.75 Million TWD | 76.83% |
| 2020 Q1 | 15.18 Million TWD | -78.14% |
| 2020 Q3 | 29.26 Million TWD | 149.38% |
| 2020 FY | 97.31 Million TWD | -57.34% |
| 2020 Q2 | 11.73 Million TWD | -22.73% |
| 2019 FY | 228.11 Million TWD | 7.62% |
| 2019 Q4 | 69.48 Million TWD | 84.28% |
| 2019 Q1 | 51.55 Million TWD | -42.94% |
| 2019 Q3 | 37.7 Million TWD | -42.14% |
| 2019 Q2 | 65.17 Million TWD | 26.41% |
| 2018 Q1 | 14.31 Million TWD | -54.22% |
| 2018 FY | 211.97 Million TWD | 46.47% |
| 2018 Q4 | 90.35 Million TWD | 105.39% |
| 2018 Q3 | 43.99 Million TWD | -30.41% |
| 2018 Q2 | 63.22 Million TWD | 341.76% |
| 2017 Q1 | 53.53 Million TWD | -37.48% |
| 2017 Q2 | 20.73 Million TWD | -61.27% |
| 2017 Q3 | 39.18 Million TWD | 88.96% |
| 2017 FY | 144.72 Million TWD | 11.65% |
| 2017 Q4 | 31.26 Million TWD | -20.21% |
| 2016 Q2 | 8.38 Million TWD | 0.0% |
| 2016 Q4 | 85.62 Million TWD | 214.44% |
| 2016 Q3 | 27.23 Million TWD | 224.96% |
| 2016 FY | 129.62 Million TWD | 8.05% |
| 2016 Q1 | 8.38 Million TWD | -82.33% |
| 2015 FY | 119.96 Million TWD | 86.29% |
| 2015 Q4 | 47.41 Million TWD | 0.0% |
| 2015 Q3 | 47.41 Million TWD | 277.45% |
| 2015 Q2 | 12.56 Million TWD | 0.0% |
| 2015 Q1 | 12.56 Million TWD | -36.08% |
| 2014 Q2 | 12.54 Million TWD | 0.0% |
| 2014 FY | 64.39 Million TWD | 363.92% |
| 2014 Q1 | 12.54 Million TWD | 292.54% |
| 2014 Q4 | 19.65 Million TWD | 0.0% |
| 2014 Q3 | 19.65 Million TWD | 56.65% |
| 2013 Q3 | 3.19 Million TWD | -14.65% |
| 2013 Q4 | 3.19 Million TWD | 0.0% |
| 2013 FY | 13.88 Million TWD | 129.09% |
| 2013 Q1 | 3.74 Million TWD | 125.39% |
| 2013 Q2 | 3.74 Million TWD | 0.0% |
| 2012 FY | -47.71 Million TWD | -0.61% |
| 2012 Q3 | -14.74 Million TWD | 0.0% |
| 2012 Q4 | -14.74 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | -47.42 Million TWD | 14.39% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -55.39 Million TWD | -1512.01% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 3.92 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 141.71 Million TWD | -10.664% |
| Sinphar Pharmaceutical Co.,Ltd. | 286.05 Million TWD | 45.175% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 280.8 Million TWD | 44.151% |
| GenMont Biotech Incorporation | 6.98 Million TWD | -2144.262% |
| Abnova (Taiwan) Corporation | 47.19 Million TWD | -232.307% |
| Adimmune Corporation | -722.74 Million TWD | 121.699% |
| Tanvex BioPharma, Inc. | -2.1 Billion TWD | 107.465% |
| Polaris Group | -1.84 Billion TWD | 108.491% |
| Energenesis Biomedical CO.,LTD. | -261.83 Million TWD | 159.896% |
| UnicoCell Biomed Co., Ltd. | -96.28 Million TWD | 262.888% |
| PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | 138.135% |